Trabeculectomy and EX-PRESS Implantation in Open-Angle Glaucoma: An Updated Meta-Analysis of Randomized Controlled Trials

Table 1

Characteristics of the included randomized clinical trials.

First author (year)	Location	No. of eyes (EX/Tr)	Type of glaucoma	Antimetabolity	Follow-up (m)
Errico (2016) [6]	Italy	16/10	Secondary OAG	Mitomycin-C 0.1 mg/mL, 5 minutes	24
Netland (2014) [8]	USA	59/61	POAG, PXFG, PG	Mitomycin-C 0.25 mg/mL, 1-2 minutes	24
Gonzalez–Rodriguez (2016) [9]	Canada	32/31	OAG	Mitomycin-C 0.4 mg/mL, 2 minutes	36
El-Saied (2017) [10]	Egypt	10/10	Secondary OAG	Mitomycin-C 0.4 mg/mL, 2 minutes	12
Dahan (2012) [11]	Israel	15/15	POAG	Mitomycin-C 0.05%, 1 minute	30
de Jong (2011) [12]	France	39/39	POAG, PXFG, PG	Mitomycin-C 0.02%	60
Arimura (2018) [13]	Japan	32/32	POAG, XFG	Mitomycin-C 0.4 mg/mL, 4 minutes	24
Mendoza–Mendieta (2016) [14]	Mexico	20/19	POAG, PXFG, PG, steroid-induced, traumatic	Mitomycin-C	19

EX: EX-PRESS; Tr: trabeculectomy; POAG: primary open-angle glaucoma; PXFG: pseudoexfoliation glaucoma; PG: pigmentary glaucoma; MMC: mitomycin-C; min: minute; m: month.